Vascular Biogenics Ltd. (VBLT) EPS Estimated At $-0.18

July 14, 2018 - By Robert Crowder

Vascular Biogenics Ltd. (NASDAQ:VBLT) Logo

Analysts expect Vascular Biogenics Ltd. (NASDAQ:VBLT) to report $-0.18 EPS on August, 13.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.18 EPS. After having $-0.24 EPS previously, Vascular Biogenics Ltd.’s analysts see -25.00 % EPS growth. The stock increased 3.53% or $0.08 during the last trading session, reaching $2.2. About 115,491 shares traded. Vascular Biogenics Ltd. (NASDAQ:VBLT) has declined 60.91% since July 14, 2017 and is downtrending. It has underperformed by 73.48% the S&P500.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Coverage

Among 4 analysts covering Vascular Biogenics (NASDAQ:VBLT), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Vascular Biogenics had 6 analyst reports since March 8, 2018 according to SRatingsIntel. The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) earned “Hold” rating by JMP Securities on Thursday, March 8. H.C. Wainwright maintained it with “Hold” rating and $300 target in Friday, May 18 report. Chardan Capital Markets downgraded the stock to “Neutral” rating in Friday, March 9 report. The rating was downgraded by Piper Jaffray to “Hold” on Thursday, March 8. H.C. Wainwright downgraded Vascular Biogenics Ltd. (NASDAQ:VBLT) on Thursday, March 8 to “Neutral” rating. The firm has “Hold” rating given on Thursday, March 22 by H.C. Wainwright.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company has market cap of $78.88 million. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. It currently has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

More notable recent Vascular Biogenics Ltd. (NASDAQ:VBLT) news were published by: Nasdaq.com which released: “VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market” on June 26, 2018, also Nasdaq.com with their article: “Publication by VBL Therapeutics Highlights MOSPD2 as a Potential New Target for Breast Cancer Therapy” published on July 10, 2018, Benzinga.com published: “54 Biggest Movers From Yesterday” on June 27, 2018. More interesting news about Vascular Biogenics Ltd. (NASDAQ:VBLT) were released by: Globenewswire.com and their article: “VBL Therapeutics Announces Closing of $15.5 Million Registered Direct Offering” published on June 27, 2018 as well as Benzinga.com‘s news article titled: “40 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: June 26, 2018.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.